In conclusion, we provide evidence that while a germline mutation in the APC gene carried by a family of FAP affected individuals is immunogenic in unaffected individuals, central tolerance mediated mechanisms likely rendered the peptide unresponsive in FAP affected members, thereby negating its use as a cancer vaccine candidate in individuals harboring this germline mutation. This evidence concerns the gene FAP and cancer.